Cargando…
Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
Background: We examined the real-world drug retention rate and safety data of Janus kinase inhibitors (JAKis) in elderly patients with rheumatoid arthritis (RA). Methods: This study enrolled 133 RA patients (≥65 years) with sufficient clinical data who were initiated with JAKis during the study peri...
Autores principales: | Temmoku, Jumpei, Miyata, Masayuki, Suzuki, Eiji, Sumichika, Yuya, Saito, Kenji, Yoshida, Shuhei, Matsumoto, Haruki, Fujita, Yuya, Matsuoka, Naoki, Asano, Tomoyuki, Sato, Shuzo, Migita, Kiyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380728/ https://www.ncbi.nlm.nih.gov/pubmed/37510700 http://dx.doi.org/10.3390/jcm12144585 |
Ejemplares similares
-
Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia
por: Temmoku, Jumpei, et al.
Publicado: (2023) -
Comparing the effectiveness and safety of Abatacept and Tocilizumab in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022) -
Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
por: Yoshida, Shuhei, et al.
Publicado: (2023) -
Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023) -
Clinical Features and Outcomes of Japanese Patients with Giant Cell Arteritis: A Comparison with Takayasu Arteritis
por: Yoshida, Shuhei, et al.
Publicado: (2023)